Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Gastritis II: Pathophysiology

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.

Gastritis III: Clinical Manifestations and Management

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Feasibility and tolerability of reduced-volume oral sulfate solution combined with elobixibat for bowel preparation before colonoscopy: a single-center pilot study.

Gastroenterology report·2026

Same author

A primary care clinic on the frontline of early cancer detection: a retrospective observational study.

BMC primary care·2026

Same author

Association of serum albumin redox state with dietary protein intake and frailty in older adults: A cross-sectional study.

Clinical nutrition ESPEN·2026

Same author

Ten-Year Trends in First- and Second-Line <i>Helicobacter pylori</i> Eradication Rates at a Regional Hospital in Japan.

Juntendo medical journal·2026

Same author

Endoscopic submucosal dissection using an S-O clip for successful en bloc resection of a circumferential colonic superficial neoplasm.

Clinical endoscopy·2026

Same author

Recurrent local and systemic hypersensitivity reactions after switching back from subcutaneous to intravenous vedolizumab in ulcerative colitis: a case presentation.

Gastroenterology report·2026

Search research articles

Related Experiment Video

Updated: May 8, 2026

Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance

Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance

Published on: July 28, 2023

[Second-line therapy for Helicobacter pylori].

Daisuke Asaoka¹, Akihito Nagahara, Mariko Hojo

¹Department of Gastroenterology, Juntendo University, School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine

|August 24, 2013

Summary

This summary is machine-generated.

Proton pump inhibitor (PPI)-based triple therapy (PPI, amoxicillin, metronidazole) remains effective for second-line Helicobacter pylori eradication in Japan, achieving high success rates. High-dose dual therapy (PPI, amoxicillin) is also a potential strategy.

More Related Videos

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Published on: June 13, 2025

Related Experiment Videos

Last Updated: May 8, 2026

Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance

Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance

Published on: July 28, 2023

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Published on: June 13, 2025

Area of Science:

Gastroenterology
Microbiology
Pharmacology

Background:

The standard second-line Helicobacter pylori eradication regimen is quadruple therapy (PPI, bismuth, tetracycline, metronidazole).
Levofloxacin- and moxifloxacin-based triple therapies are emerging alternatives.
In Japan, PPI-based triple therapy (PPI, amoxicillin, metronidazole) is utilized for second-line treatment.

Purpose of the Study:

To evaluate the efficacy of PPI-based triple therapy as a second-line regimen for H. pylori eradication in Japan.
To explore alternative second-line treatment strategies following first-line eradication failure.

Main Methods:

Review of second-line eradication regimens for H. pylori.
Analysis of the effectiveness of PPI-based triple therapy (PPI, amoxicillin, metronidazole) in the Japanese context.
Consideration of high-dose dual therapy (PPI, amoxicillin) as a treatment option.

Main Results:

PPI-based triple therapy (PPI, amoxicillin, metronidazole) demonstrates a high second-line eradication rate (approximately 90% ITT) in Japan.
This regimen is considered a useful option for H. pylori eradication after initial treatment failure.
High-dose dual therapy with PPI and amoxicillin for two weeks shows potential as a post-failure strategy.

Conclusions:

PPI-based triple therapy (PPI, amoxicillin, metronidazole) is an effective and viable second-line H. pylori eradication strategy in Japan.
Further investigation into high-dose dual therapy (PPI, amoxicillin) may offer additional treatment options.